These findings caused an impulse in the discovery of novel biomarkers of NASH HCC and numerous chemopreventive and therapeutic studies with mTOR inhibitors in NAFLD/NASH/HCC [23]. The gene discussed is MTOR; the disease is metabolic dysfunction-associated steatotic liver disease.